Back to Search
Start Over
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.
- Source :
-
Internal medicine (Tokyo, Japan) [Intern Med] 2017 Nov 01; Vol. 56 (21), pp. 2895-2898. Date of Electronic Publication: 2017 Sep 25. - Publication Year :
- 2017
-
Abstract
- We report an 80-year-old woman with EGFR-mutant lung adenocarcinoma with multiple brain metastases (BMs). All lesions including BM showed a successful resolution after initiating daily 150 mg erlotinib. However, a grade 2 bilirubin-increase developed, and it was necessary to reduce the dose of erlotinib to 50 mg every other day, which aggravated BM. Switching erlotinib to afatinib led to the resolution of BM without an increase in the bilirubin level. Our results indicate that afatinib is an important treatment option when erlotinib-induced hepatotoxicity develops, regardless of the patients' age. Particularly in those patients with BM, switching to afatinib may be preferable to reducing the dose of erlotinib.
- Subjects :
- Adenocarcinoma of Lung
Afatinib
Aged, 80 and over
Chemical and Drug Induced Liver Injury
Dose-Response Relationship, Drug
ErbB Receptors genetics
Erlotinib Hydrochloride administration & dosage
Erlotinib Hydrochloride adverse effects
Female
Humans
Adenocarcinoma pathology
Brain Neoplasms drug therapy
Brain Neoplasms secondary
Lung Neoplasms pathology
Quinazolines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1349-7235
- Volume :
- 56
- Issue :
- 21
- Database :
- MEDLINE
- Journal :
- Internal medicine (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 28943548
- Full Text :
- https://doi.org/10.2169/internalmedicine.8638-16